Cystadenocarcinoma, Serous: all 122 studies

Page 1 of 2. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.

• Exploratory Study on HER2 Detection Method and Positive Threshold for High-grade Serous Adenocarcinoma of the OvaryRecruitingNCT06883487
• High Definition Profiling of Ovarian Cancer AscitesNot yet recruitingNCT06553742
• Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPiNot yet recruitingNCT06161272Phase 2
• First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian CancerNot yet recruitingNCT06063070Phase 2
• Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian CancerRecruitingNCT05961124Phase 2
• Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)RecruitingNCT05601700Phase 3
• Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous CarcinomaRecruitingNCT05537844
• AMT-151 in Patients With Selected Advanced Solid TumoursRecruitingNCT05498597Phase 1
• Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian CancerRecruitingNCT05080556Phase 2
• Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOCRecruitingNCT04846933Not applicable
• Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous CarcinomaRecruitingNCT04716686Phase 2
• A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid TumorsTerminatedNCT05949632Phase 1/2Results posted
• BrUOG 390: Neoadjuvant Treatment With TalazoparibTerminatedNCT04598321Phase 1Results posted
• A Study of Adavosertib as Treatment for Uterine Serous CarcinomaCompletedNCT04590248Phase 2Results posted
• A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)TerminatedNCT03824704Phase 2Results posted
• Ribociclib and Letrozole Treatment in Ovarian CancerActive, not recruitingNCT03673124Phase 2Results posted
• The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer SurvivorsTerminatedNCT03641287Not applicableResults posted
• Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal AdenocarcinomaTerminatedNCT03610490Phase 2Results posted
• Lavage of the Uterine Cavity for Diagnosis of Ovarian CancerTerminatedNCT03606486Not applicableResults posted
• Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of MalignancyCompletedNCT03593681Results posted
• Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 MutationCompletedNCT02953457Phase 2Results posted
• Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT02923739Phase 2Results posted
• Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast CancerCompletedNCT02898207Phase 1Results posted
• Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02853318Phase 2Results posted
• Copanlisib in Treating Patients With Persistent or Recurrent Endometrial CancerCompletedNCT02728258Phase 2Results posted
• Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02713386Phase 1/2Results posted
• Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT02283658Phase 2Results posted
• Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine CancerTerminatedNCT02112552Phase 2Results posted
• Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity CancerCompletedNCT02101788Phase 2/3Results posted
• Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial CancerStatus unknownNCT02065687Phase 2/3Results posted
• Dalantercept in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT01642082Phase 2Results posted
• Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial CancerCompletedNCT01307631Phase 2Results posted
• Phase II ABT-888 With CyclophosphamideCompletedNCT01306032Phase 2Results posted
• Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian CancerTerminatedNCT01275664Not applicableResults posted
• Nintedanib in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT01225887Phase 2Results posted
• Trebananib in Treating Patients With Persistent or Recurrent Endometrial CancerCompletedNCT01210222Phase 2Results posted
• Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT01132820Phase 2Results posted
• First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube CancerCompletedNCT01097746Phase 2Results posted
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
• Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial CancerCompletedNCT01005329Phase 2Results posted
• Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or CisplatinCompletedNCT00993616Phase 2Results posted
• Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial CancerStatus unknownNCT00942357Phase 3Results posted
• A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00939809Phase 2Results posted
• Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00888615Phase 2Results posted
• Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00888173Phase 2Results posted
• Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial CancerStatus unknownNCT00807768Phase 3Results posted
• Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum CancerCompletedNCT00551070Phase 2Results posted
• Papillary Serous Carcinoma of the EndometriumCompletedNCT00515073Phase 2Results posted
• Gleevec/Taxol for Patients With Uterine Papillary Serous CarcinomaTerminatedNCT00506779Phase 1/2Results posted
• Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial CancerStatus unknownNCT00492778Phase 2Results posted
• Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial CancerCompletedNCT00478426Phase 2Results posted
• Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous ChemotherapyCompletedNCT00466960Phase 2Results posted
• Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial CancerCompletedNCT00416455Phase 1/2Results posted
• AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube CancerCompletedNCT00275028Phase 2Results posted
• Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00262847Phase 3Results posted
• A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous CarcinomaCompletedNCT00231868Phase 2Results posted
• Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube CancerStatus unknownNCT00108745Phase 3Results posted
• Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial CancerCompletedNCT00072176Phase 2Results posted
• Erlotinib Plus Carboplatin and Paclitaxel in Ovarian CarcinomaCompletedNCT00059787Phase 2Results posted
• Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial CancerCompletedNCT00006011Phase 3Results posted
• Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian CancerWithdrawnNCT06393751Phase 1/2
• A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the OvaryTerminatedNCT05538624Phase 1/2
• Role of the ATP7A Transporter in Ovarian CancerCompletedNCT05490407Not applicable
• PET/MRI in Endometrial CancerWithdrawnNCT05390021Not applicable
• Combination of Olaparib and Navitoclax in Women with HGSC and TNBCActive, not recruitingNCT05358639Phase 1
• Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor TherapyWithdrawnNCT05295589Phase 2
• Niraparib in High-grade Endometrial Cancer TrialWithdrawnNCT05289648Early Phase 1
• A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid TumorsCompletedNCT05074472Phase 1/2
• A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)TerminatedNCT05001282Phase 1/2
• A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous CarcinomaCompletedNCT04814108Phase 2
• A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS MutationActive, not recruitingNCT04625270Phase 2
• Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian CancerActive, not recruitingNCT04575961Phase 2
• PDL1 in Ovarian High Grade Serous CarcinomaCompletedNCT04507191
• Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.CompletedNCT04458597Not applicable
• Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma.CompletedNCT04284631
• A Study of Various Treatments in Serous or p53 Abnormal Endometrial CancerTerminatedNCT04159155Phase 2/3
• Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)Status unknownNCT04055038Phase 2/3
• Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and RadiationWithdrawnNCT04030000Phase 1/2
• Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube CancersTerminatedNCT03924245Phase 1
• Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial CancerWithdrawnNCT03836157Phase 2
• Immune Repertoire of Ovarian HGSCStatus unknownNCT03794115
• Non-coding RNA in the Exosome of the Epithelia Ovarian CancerStatus unknownNCT03738319
• Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)CompletedNCT03648489Phase 2
• Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedNCT03552471Phase 1
• Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer PatientsStatus unknownNCT03509246Phase 2
• Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene MutationCompletedNCT03285802Phase 2/3
• Biomarkers for Early Detection of Ovarian Cancer Using Uterine LavageStatus unknownNCT03150121Not applicable
• French National Registry of Rare Peritoneal Surface MalignanciesStatus unknownNCT02834169
• Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 2
• Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast CancerWithdrawnNCT02627430Phase 1
• Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02316834Early Phase 1
• Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing SurgeryCompletedNCT02315469
• To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal CancersCompletedNCT02179970Phase 1
• Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerWithdrawnNCT02050009Phase 1
• Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological CancersCompletedNCT02020707Phase 1
• Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT01935973Phase 1
• Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT01504126Early Phase 1
• Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing ChemotherapyWithdrawnNCT01492920Phase 3
• EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT01489371Phase 1
• Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT01459380Phase 1

← Cystadenocarcinoma, Serous overview